International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Pancreatic cancer is a formidable disease with a high mortality rate, characterized by its aggressive nature, limited treatment options, and a propensity for metastasis. Within this complex landscape, a subgroup of cells known as pancreatic cancer stem cells (PCSCs) has emerged as a critical player [1, 2]. These cells possess unique characteristics that contribute to disease progression, treatment resistance, and the potential for distant spread. Understanding the implications of cell surface markers, prognosis, resistance mechanisms, metastatic potential, and treatment strategies associated with PCSCs is crucial for advancing our knowledge and improving outcomes for patients battling this devastating cancer [3- 5].

Cell surface markers and identification

PCSCs, analogous to their normal stem cell counterparts, exhibit distinct cell surface markers that set them apart from the bulk of the tumor. Identification and isolation of these markers, such as CD44, CD133, and EpCAM, allow for a deeper understanding of PCSC biology and facilitate their targeting for therapeutic purposes [6 ]. The presence of these markers not only aids in the characterization of PCSCs but also holds potential as prognostic indicators.

Prognostic significance

The presence and abundance of PCSCs within pancreatic tumors have been associated with poorer prognosis. These cells are thought to contribute to tumor initiation, maintenance, and recurrence. Their ability to self-renew and differentiate into various cell types fuels tumor growth, and their survival under adverse conditions contributes to therapeutic resistance. Therefore, identifying PCSCs in patient samples could provide valuable insights into disease progression and guide treatment decisions [7, 8].

Resistance mechanisms

PCSCs are often resistant to conventional chemotherapy and radiation treatments, contributing to the limited success of these approaches. Their inherent plasticity and adaptive capabilities enable them to evade the effects of therapeutic interventions. Understanding the molecular and cellular mechanisms responsible for PCSC resistance is imperative for designing strategies to overcome treatment barriers and improve patient outcomes [8].

Metastatic potential

Metastasis is a defining feature of aggressive cancers, including pancreatic cancer. PCSCs are believed to play a pivotal role in this process, as they possess the ability to disseminate from the primary tumor, survive in the circulation, and establish secondary tumors in distant organs. Targeting PCSCs may hold the key to preventing or mitigating the spread of pancreatic cancer, thereby enhancing the overall efficacy of therapeutic interventions [10, 11].

Treatment strategies

Developing effective treatment strategies for pancreatic cancer remains a significant challenge. Given their central role in disease progression, PCSCs have garnered attention as potential therapeutic targets. Strategies aimed at disrupting PCSC self-renewal pathways, promoting differentiation, and sensitizing these cells to existing treatments is being explored. Additionally, immunotherapeutic approaches that harness the immune system's ability to recognize and eliminate PCSCs are being investigated [12].

Conclusion

The comprehensive analysis of pancreatic cancer stem cells reveals their multifaceted role in tumor progression, metastasis, therapy resistance, and poor prognosis. Understanding the association of these cells with cell surface markers, their impact on clinical outcomes, and their contributions to treatment resistance and metastasis is pivotal for developing effective therapeutic strategies. Targeting pancreatic CSCs offers a promising avenue for improving the currently limited treatment options for pancreatic cancer and potentially transforming the landscape of patient care.

Acknowledgement

None

Conflict of Interest

None

1. de Wilde RF, Besselink MG, van der Tweel I, de Hingh IHJT, van Eijck CHJ, et al. (2012) Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 99: 404-410.

Indexed at, Google Scholar, Crossref

2. Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, et al. (2011) Improving outcome for patients with pancreatic cancer through centralization. Br J Surg 98: 1455-1462.

Indexed at, Google Scholar, Crossref

3. Kostalas M, Nageswaran H, Froghi S, Riga A, Kumar R, et al. (2018) Centralisation for resection of the pancreatic head: a comparison of operative factors and early outcomes during the evolving unit and tertiary unit phases at a UK institution. Am J Surg 216: 310-313.

Indexed at, Google Scholar, Crossref

4. Polonski A, Izbicki JR, Uzunoglu FG (2019) Centralization of pancreatic surgery in Europe. J Gastrointest Surg 23: 2081-2092.

Indexed at, Google Scholar, Crossref

5. Han SS, Park SJ, Kim SH (2012) Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer. Pancreas 41: 102-106.

Indexed at, Google Scholar, Crossref

6. Ravikumar R, Sabin C, Abu Hilal M (2017) Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. Br J Surg 104: 1539-1548.

Indexed at, Google Scholar, Crossref

7. Dua MM, Tran TB, Klausner J (2015) Pancreatectomy with vein reconstruction: technique matters. HPB 17: 824-831.

Indexed at, Google Scholar, Crossref

8. Lee DY, Mitchell EL, Jones MA (2010) Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreatic oduodenectomy. J Vasc Surg 51: 662-666.

Indexed at, Google Scholar, Crossref

9. Mizrak D, Brittan M, Alison M (2008) CD133: molecule of the moment. J Pathol 214: 3-9.

Indexed at, Google Scholar, Crossref

10. Li T, Su Y, Mei Y, Leng Q, Leng B (2010) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 90: 234-244.

Indexed at, Google Scholar, Crossref

11. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG (2008) PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68: 1820-1825.

Indexed at, Google Scholar, Crossref

12. Huang R, Wang S, Wang N, Zheng Y, Zhou J (2020) CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating beta-catenin/STAT3 signaling. Cell Death Dis 11: 234.

Indexed at, Google Scholar, Crossref